RESEARCH / PARTICIPATIONBack to the library
← Find a study
Recruiting · registry status

Ambroxol for Parkinson's with a GBA gene change

Researchers are comparing ambroxol tablets with placebo to investigate treatment effects in this group.

Testing a treatment or activity · Study reference: NL-OMON52316

Plain-language introduction written with AI from the registry; not independently checked by a clinician. Read the original details below ↓

This registry record was last updated over six months ago, or its update date is missing. Recruitment may have changed. Confirm with the team before making plans.

Open the official registry record ↗

Follow this study

Looking for volunteers

Start (reported date)
2023-06-01

Planned dates can move. A study finishing does not tell us when a paper will be published.

No results summary has been confirmed in the registry records we imported. See connected papers below; we keep checking after recruitment ends.

Changes we have recorded
  • 2026-10-11 — recruiting

These are dates we observed a change, not necessarily the dates it happened.

Papers connected to this study

No connected paper has been found yet. The tracker checks the growing library for study identifiers and registry-linked publications.

Who can join?

Ages 18 to 99 · Ask the team who can join

These are starting points, not the full rules. The research team can tell you whether the study is right for your situation.

Read all the rules for taking part

Sex eligibility reported by registry: Not reported

Inclusion criteria: - Diagnosis of Parkinson*s disease, according to Movement Disorders Society (MDS) criteria <10 years - PD patients carrying a GBA1 mutation - Willingness to cooperate and sign written informed consent - Willing and able to self-administer oral ambroxol medication Exclusion criteria: - The refusal to be informed about an unforeseen clinical finding - Pregnant or breast feeding women - Use of an implanted Deep Brain Stimulation (DBS) system - MRI imcompatible implants in the body
Full study name & original research details

Official study title

The Dutch Parkinson GBA Ambroxol trial (DUPARG-AMBROXOL): A randomised, double-blind, placebo-controlled, single-center trial with Ambroxol in Parkinson patients with a GBA mutation - The Dutch Parkinson GBA Ambroxol trial

Short title used by the registry

The Dutch Parkinson GBA Ambroxol trial (DUPARG-AMBROXOL): A randomised, double-blind, placebo-controlled, single-center trial with Ambroxol in Parkinson patients with a GBA mutation

Original description

Intervention: Patients will start with oral tablets of Ambroxol 600mg or placebo, which will increase with 600mg per week, to a maximum of 3 times 600mg a day for a period of 48 weeks. At 48 weeks all participants will switch to placebo during the last 12 weeks. Primary outcome: The primary endpoint is the comparison of MDS-UPDRS part III motor subscale in the practically defined OFF medication state at 60 weeks after a 12 week washout period. Secondary outcome: Secondary endpoints are: - Safety and tolerability by examine adverse events - F-DOPA PET - MRI - Montreal Cognitive Assessment (MoCA) - Non-Motor Symptoms scale (NMSS) - Parkinson*s Disease 39 item Quality of life questionnaire (PDQ-39) - GCase activity measured using a flow cytometry based assay of peripheral blood mononuclear cells (PBMCs)

Conditions reported: Parkinson Parkinson's disease;10028037

Registry records for this study

Records are joined using registration identifiers. Titles alone do not establish that two studies are the same.

Study type
Interventional
Interventions
Patients will start with oral tablets of Ambroxol 600mg or placebo, which will increase with 600mg per week, to a maximum of 3 times 600mg a day for a period of 48 weeks. At 48 weeks all participants will switch to placebo during the last 12 weeks.
Phases
2
Sponsor
Universitair Medisch Centrum Groningen
Start date reported by registry
2023-06-01 (reported)

Registry updated: Not reported · Status last verified by the registry submitter: Not reported

Registry records retrieved 2026-10-13 (UTC). Individual records may have older updates. Recruitment and eligibility must be confirmed with the study team.

Contact the research team

Public study contacts supplied to the registry. Ask whether recruitment is still open and what participation involves.

Study locations

Site status can differ from overall study status. “Status not reported” means local availability needs confirmation. Remote participation and travel arrangements must be checked with the team.

Facility not reported

Netherlands

Status not reported

The original descriptions and participation rules come from the registry. Participation is voluntary and does not guarantee benefit.